CEDILLA THERAPEUTICS
Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.
CEDILLA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cedillatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
138.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aditxt Therapeutics
Aditxt Therapeutics is a biotechnology company that develops a novel nucleic acid-based technology.
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Alkermes
Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Iterion Therapeutics
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics.
Casma Therapeutics
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
DermBiont
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
Egle Therapeutics
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Flare Therapeutics
Flare Therapeutics is a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Gismo Therapeutics
Gismo Therapeutics, a biotechnology startup, develops small-molecule therapeutics for the treatment of Alzheimer’s and Parkinson’s diseases.
IMMvention Therapeutix
IMMvention Therapeutix is a biotechnology company developing novel small molecule pan-inflammasome inhibitors for inflammatory diseases.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Kymera Therapeutics
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Ikena Oncology
Ikena Oncology is a biotechnology company that advances new immunometabolic therapies for cancer.
Ligature Therapeutics
Ligature Therapeutics is a biotech company that develops small molecules for targeted protein degradation to treat intractable diseases.
NovelMed Therapeutics
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
QED Therapeutics
QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders.
Relay Therapeutics
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Motus Therapeutics
Motus Therapeutics is a biotechnology company developing peptide therapeutics for the treatment of metabolic diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Silver Creek Pharmaceuticals
Silver Creek Pharmaceuticals is a biotechnology company, develops protein therapeutics to treat cardiovascular diseases.
Speratum
Speratum is a biotechnology company dedicated to research and development (R&D) of targeted molecular therapies for cancer treatment.
Theron Pharmaceuticals
Theron Pharmaceuticals is a biotechnology company that develops therapeutic products for the treatment of chronic respiratory diseases.
Trefoil Therapeutics
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Versartis
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.
Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
X-Biotix Therapeutics
X-Biotix Therapeutics is a biotechnology company specializing in the development of small molecule antibiotic scaffolds.
Current Advisors List
Current Employees Featured
Founder
Investors List
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Cedilla Therapeutics
Woodline Partners
Woodline Partners investment in Series B - Cedilla Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Cedilla Therapeutics
Logos Capital
Logos Capital investment in Series B - Cedilla Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series B - Cedilla Therapeutics
Schroder Adveq
Schroder Adveq investment in Series B - Cedilla Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series B - Cedilla Therapeutics
Boxer Capital
Boxer Capital investment in Series B - Cedilla Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Cedilla Therapeutics
Eli Lilly
Eli Lilly investment in Series B - Cedilla Therapeutics
Official Site Inspections
http://www.cedillatx.com
- Host name: 100.19.231.35.bc.googleusercontent.com
- IP address: 35.231.19.100
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Cedilla Therapeutics"
Cedilla Therapeutics - LinkedIn
Cedilla Therapeutics | 5,207 followers on LinkedIn. A New Dimension in Precision Oncology | For 60 years, sequence and structure has been the primary lens to understand protein function. It’s ...See details»
Cedilla Therapeutics Expands Leadership Team with …
Nov 16, 2021 Follow our journey at www.cedillatx.com and LinkedIn. Contacts Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. [email protected] 212-362-1200See details»
Cedilla Therapeutics - VentureRadar
Cedilla Therapeutics is a private biotechnology company developing targeted small molecule medicines for the treatment of cancer and other diseases... ... Find out ...See details»
Cedilla Therapeutics Completes $82.6M Series B …
Oct 25, 2021 Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 milSee details»
Cedilla Therapeutics - Craft
Cedilla Therapeutics has 5 employees at their 1 location and $81.2 m in total funding,. See insights on Cedilla Therapeutics including office locations, competitors, revenue, financials, …See details»
Cedilla Therapeutics - VentureRadar
Open PageRank: 6,697,148 | cedillatx.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times …See details»
Cedilla Therapeutics Completes $82.6M Series B Financing
Oct 25, 2021 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised …See details»
Series B - Cedilla Therapeutics - 2021-10-25 - Crunchbase
Oct 25, 2021 Organization Name . Cedilla Therapeutics . Announced Date Oct 25, 2021; Funding Type Series B; Funding Stage Early Stage Venture; Money Raised . $25M. Lead …See details»
Cedilla Therapeutics Announces $57.6 Million Series B Financing
Oct 13, 2020 For more information, please visit www.cedillatx.com or follow us on LinkedIn. Contacts Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. …See details»
Cedilla Therapeutics Expands Leadership Team with Key
Nov 16, 2021 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced appointments …See details»
Cedilla Therapeutics - Company info. interviews, news
Oct 18, 2022 Protein Degraders Take Industry By Storm Oct. 18, 2022 Proteins are essential components of living matter — they function as building blocks for cells and tissues, as well as …See details»
Cedilla Therapeutics to Present at Upcoming Investor Conferences
Feb 4, 2022 Cedilla Therapeutics announces that President & CEO Alexandra Glucksmann, Ph.D., will present at two upcoming investor conferences in February.See details»
Cedilla Therapeutics Unveils Lead Programs for the Conditional ...
Oct 21, 2021 Cedilla Therapeutics today revealed its two lead conditional inhibitor programs: an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain …See details»
Cedilla Therapeutics Expands Leadership Team - citybiz
Nov 16, 2021 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced appointments …See details»
Cedilla Therapeutics Unveils Lead Drug Programs Targeting TEAD, …
Oct 21, 2021 NEW YORK – Precision oncology startup Cedilla Therapeutics on Thursday unveiled its two lead drug programs, a TEAD inhibitor for the treatment of solid tumors and a …See details»
Cedilla Therapeutics Unveils Lead Programs for the Conditional ...
Oct 21, 2021 --Conditional modulation of proteins in their functional state opens a new dimension in precision oncology----IND-enabling studies expected to initiate in 1H 2022 for …See details»
Cedilla Therapeutics Unveils Lead Programs for the Conditional ...
Oct 22, 2021 Follow our journey at www.cedillatx.com and LinkedIn. SOURCE: Cedilla Therapeutics. Post Views: 223. Custom Report. La Merie Publishing offers the service of …See details»
Cedilla Therapeutics Completes $82.6M Series B Financing
Oct 25, 2021 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised …See details»
Cedilla and HitGen Announce Research Collaboration Focused on …
Nov 30, 2020 For more information, visit www.cedillatx.com. Investor Contact (Cedilla): Hannah Deresiewicz Stern Investor Relations, Inc. [email protected] 212-362-1200 …See details»